HomeCompareTISNF vs PFE

TISNF vs PFE: Dividend Comparison 2026

TISNF yields 2.55% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TISNF wins by $190.76M in total portfolio value
10 years
TISNF
TISNF
● Live price
2.55%
Share price
$20.00
Annual div
$0.51
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$190.81M
Annual income
$177,442,209.22
Full TISNF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TISNF vs PFE

📍 TISNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTISNFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TISNF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TISNF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TISNF
Annual income on $10K today (after 15% tax)
$216.75/yr
After 10yr DRIP, annual income (after tax)
$150,825,877.84/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TISNF beats the other by $150,803,557.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TISNF + PFE for your $10,000?

TISNF: 50%PFE: 50%
100% PFE50/50100% TISNF
Portfolio after 10yr
$95.43M
Annual income
$88,734,233.97/yr
Blended yield
92.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TISNF
No analyst data
Altman Z
5.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TISNF buys
0
PFE buys
0
No recent congressional trades found for TISNF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTISNFPFE
Forward yield2.55%6.13%
Annual dividend / share$0.51$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$190.81M$49.6K
Annual income after 10y$177,442,209.22$26,258.71
Total dividends collected$189.79M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TISNF vs PFE ($10,000, DRIP)

YearTISNF PortfolioTISNF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,210$510.00$9,153$693.39+$2.1KTISNF
2$13,063$1,068.62$8,593$849.25+$4.5KTISNF
3$16,305$2,327.64$8,336$1,066.78+$8.0KTISNF
4$22,877$5,430.50$8,437$1,384.80+$14.4KTISNF
5$38,720$14,241.62$9,013$1,875.40+$29.7KTISNF
6$86,485$45,054.68$10,306$2,680.72+$76.2KTISNF
7$280,640$188,100.64$12,820$4,101.38+$267.8KTISNF
8$1,441,174$1,140,888.73$17,673$6,826.70+$1.42MTISNF
9$12,493,117$10,951,061.05$27,543$12,591.86+$12.47MTISNF
10$190,809,844$177,442,209.22$49,560$26,258.71+$190.76MTISNF

TISNF vs PFE: Complete Analysis 2026

TISNFStock

TIS Inc. provides information technology (IT) services in Japan and internationally. The company operates through Offering Service Business, Business Process Management, Financial IT Business, Industrial IT Business, and Regional IT Solutions segments. The Offering Service Business segment provides knowledge-intensive IT services, including digital marketing, healthcare, and business management information. The Business Process Management segment offers outsourcing, contact center, and system configuration services, as well as DX support paralleling use of IT solutions. The Financial IT Business segment supports business progress using expert business and operating know-how to the finance industry. The Industrial IT Business segment provides services for client's operations, including projects for members of energy, and processing- and assembly-based manufacturing and engineering sectors, as well as ERP consulting and modernization services to clients. The Regional IT Solutions segment offers IT professional services and collects and develops this know-how as the source of solutions to support efforts to address issues and promote business activities. The company is also involved in the provision of consulting services related to IT management; development of IT systems; and development and maintenance of systems using business packages to address client-side management and business issues, as well as offers on-demand IT resources using SaaS and other categories of cloud computing, including system operation through company-run data centers. In addition, it engages in the sale and maintenance of hardware, such as servers and network equipment, and software. It serves clients in the credit card, banking, insurance and other financial, manufacturing, distribution, service, public, and other sectors. The company was formerly known as IT Holdings Corporation and changed its name to TIS Inc. in July 2016. TIS Inc. was founded in 1971 and is headquartered in Tokyo, Japan.

Full TISNF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TISNF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TISNF vs SCHDTISNF vs JEPITISNF vs OTISNF vs KOTISNF vs MAINTISNF vs JNJTISNF vs MRKTISNF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.